Investor Alert: Pomerantz Law Firm Investigates SELLAS Life Sciences Group
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) and certain of its officers and directors on behalf of investors. The investigation follows a report that the company's phase 3 clinical trial for Galinpepimut-S reached its pre-specified endpoint with 80 patient deaths but had not yet released results as of August 28, 2026. On this news, SELLAS' stock price dropped $2.00 per share (13.15%) to close at $13.21 on the same day. Pomerantz LLP is a well-known firm in corporate and securities litigation with offices across multiple global locations.
Tickers: $SLS